Literature DB >> 16048252

Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences.

Janusz Witowski1, Achim Jörres.   

Abstract

This review provides an overview of recent studies that show the clinical significance of biocompatibility of peritoneal dialysis fluids.

Mesh：

Substances：

Year:  2005        PMID： 16048252

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN： 0896-8608            Impact factor:   1.756


  9 in total

1.  Dialysate CA125 levels after 5 years on continuous peritoneal dialysis.

Authors:  Cengiz Candan; Pınar Turhan; Lale Sever; Mahmut Civilibal; Nur Canpolat; Salim Caliskan; Ozgur Kasapcopur; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2011-01-29       Impact factor: 3.714

2.  Trials (and tribulations) of biocompatible peritoneal dialysis fluids.

Authors:  David W Johnson; Yeoungjee Cho; Fiona G Brown
Journal:  Perit Dial Int       Date:  2012 May-Jun       Impact factor: 1.756

Review 3.  Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions.

Authors:  Anneleen Pletinck; Raymond Vanholder; Nic Veys; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2012-07-10       Impact factor: 28.314

4.  Biocompatibility of a new PD solution for Japan, Reguneal™, measured as in vitro proliferation of fibroblasts.

Authors:  Bart Dioos; Goedele Paternot; Rose-Marie Jenvert; Annick Duponchelle; Mark R Marshall; Migaku Nakajima; Edward Ramirez Ganoza; James A Sloand; Anders P Wieslander
Journal:  Clin Exp Nephrol       Date:  2018-06-20       Impact factor: 2.801

5.  The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

6.  Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.

Authors:  David W Johnson; Margaret Clarke; Vanessa Wilson; Feidhlim Woods; Fiona G Brown
Journal:  BMC Nephrol       Date:  2010-09-16       Impact factor: 2.388

Review 7.  Selection of modalities, prescription, and technical issues in children on peritoneal dialysis.

Authors:  Enrico Verrina; Valeria Cappelli; Francesco Perfumo
Journal:  Pediatr Nephrol       Date:  2008-06-03       Impact factor: 3.714

8.  The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Nephrol Dial Transplant       Date:  2012-08-01       Impact factor: 5.992

9.  Biocompatible dialysis fluids for peritoneal dialysis.

Authors:  Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.